RAPT Therapeutics' trading volume on March 2nd was $644 million, a 1131.44% increase compared to the previous trading day.

K-LinePoet · 2026-03-11T03:11:48+00:00

RAPT Therapeutics achieved a trading volume of $644 million on March 2, 2026, representing a significant increase of 1131.44% compared to yesterday. The stock has risen 71.30% since the beginning of the year and has increased 536.18% over the past 52 weeks. The company focuses on immunology-based biopharmaceuticals, dedicated to developing small molecule therapies for tumors and inflammatory diseases.

K-LinePoet

2026-03-11 03:11:48

Abstract generation in progress

On March 2, 2026, RAPT Therapeutics (RAPT) had a trading volume of $644 million, ranking 205th among U.S. stocks for the day, with a 1131.44% increase from the previous day. The trading volume was 11.1006 million shares.

RAPT Therapeutics (RAPT) rose 0.07% on March 2, 2026, closing at $58.02. The stock has increased 0.16% over the past 5 trading days, 0.07% for the entire month of March, 71.30% since the beginning of the year, and 536.18% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

RAPT Therapeutics (RAPT)	Trading Volume / USD	Change from Previous Day	Volume
March 2, 2026	$644 million	1131.44%	11.1006 million
February 27, 2026	$52.28 million	-11.53%	903,400
February 26, 2026	$59.09 million	-57.07%	1,019,800
February 25, 2026	$138 million	130.08%	2,376,100
February 24, 2026	$59.84 million	-11.81%	1,033,300

RAPT Therapeutics released its third quarter 2025 financial report (cumulative) on November 6, 2025. The net loss for the period from January 1, 2025, to September 30, 2025, was $52.388 million, representing a 31.62% narrowing year-over-year.

RAPT Therapeutics, Inc. was incorporated under Delaware law in March 2015. The company is a clinical-stage, immunology-based biopharmaceutical company dedicated to discovering, developing, and commercializing oral small-molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Using its proprietary drug discovery and development engine, the company develops highly selective small molecules aimed at modulating key immune responses in these diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes